The DOI matches its Crossref record; 228 of the 231 references it cites were found in a registry or an index.
From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
Open accessAbstract
The worldwide prevalence of non-alcoholic fatty liver disease (NAFLD) is estimated to have reached 25% or more in adults. NAFLD is prevalent in obese individuals, but may also affect non-obese insulin-resistant individuals. NAFLD is associated with a 2- to 3-fold increased risk of developing type 2 diabetes (T2D), which may be higher in patients with more severe liver disease - fibrosis increases this risk. In NAFLD, not only the close association with obesity, but also the impairment of many metabolic pathways, including decreased hepatic insulin sensitivity and insulin secretion, increase the risk of developing T2D and related comorbidities. Conversely, patients with diabetes have a higher prevalence of steatohepatitis, liver fibrosis and end-stage liver disease. Genetics and mechanisms involving dysfunctional adipose tissue, lipotoxicity and glucotoxicity appear to play a role. In this review, we discuss the altered pathophysiological mechanisms that underlie the development of T2D in NAFLD and vice versa. Although there is no approved therapy for the treatment of NASH, we discuss pharmacological agents currently available to treat T2D that could potentially be useful for the management of NASH.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“which however could be part of the therapeutic action (lipid partitioning with the expansion of subcutaneous adipose tissue) [36].”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [36]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Self-citationEASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s002 · Cited by 3,159
Vernon, G. C., Baranova, A. V., & Younossi, Z. M. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04724.x · Cited by 3,116
Flagged first, then by citations
3 of the 231 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Gastaldelli, 2014, Chapter 3: Pathophysiology of Prediabetes: Role of Lipotoxicity?, Volume 1, 31
Cited by
Sorted by citations
Items 401–456 of 456
Lin, Y., Zhang, Z., Zhong, J.-Q., Wang, Z., Peng, Y.-T., Lin, Y.-M., Zhang, H.-P., & Tian, J.-Q. (2023) · medRxiv · doi:10.1101/2023.12.11.23299784
Miranda, G., & Herman Vildozola, G. (2023) · Revista de Gastroenterología del Perú · doi:10.47892/rgp.2023.434.1535
Hrytsyshyn, L. M., & Popovych, Y. I. (2024) · Art of Medicine · doi:10.21802/artm.2024.1.29.33
Nonalcoholic fatty liver disease: What comes before and what are the consequences?
Bril, F. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-88426-6.00017-8
Yen, F., Hou, M., Wei, J. C., Shih, Y., Hwu, C., & Hsu, C. (2024) · Figshare · doi:10.6084/m9.figshare.24940527
The liver sinusoid in chronic liver disease: NAFLD and NASH
Kwanten, W. J., & Francque, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95262-0.00012-7
Evaluation of Gremlin-1 as a therapeutic target in metabolic dysfunction-associated steatohepatitisPreprint
Horn, P., Norlin, J., Almholt, K., Viuff, B. M., Galsgaard, E. D., Hald, A., Zosel, F., Demuth, H., Poulsen, S., Nørby, P. L., et al. (2024) · eLife · doi:10.7554/elife.95185.1
Horn, P., Norlin, J., Almholt, K., Viuff, B. M., Galsgaard, E. D., Hald, A., Zosel, F., Demuth, H., Poulsen, S., Nørby, P. L., et al. (2024) · eLife · doi:10.7554/elife.95185.1.sa0
Wan, S., Li, M., Lu, S., Zhai, Z., Wu, Y., & Gong, W. (2024) · Research Square · doi:10.21203/rs.3.rs-4760695/v1
GLP-1 Agonists for Weight Loss and Beyond
Quinter, C., Motilall, H., & Maberry, K. (2024) · Transformative Medicine · doi:10.54299/tmed/curq6915
Davidson, J. A., Brewer, H. R., Rice, C. T., Carvalho, S. J., & Kim, Y. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-095761
Effects of Lifestyle Interventions on Metabolic Dysfunction-Associated Steatotic Liver Disease
Sharma, A. R., & Barb, D. (2025) · Springer eBooks · doi:10.1007/978-3-031-82888-1_10
Advances in the Pathogenesis of Metabolism-Related Fatty Liver Disease
苏, 红. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.1541234
Bzoma, M., Bochenek, H., Kamiński, P., Czerepak, I., Gugulska, J., Bielicka, A., Szwarc, T., Kałwik, M., Niewczas, K., & Brzozowska, A. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3493
Klotho: A possible diagnostic biomarker and therapeutic target in diabetes complications
Hejrati, A., Zabihi, T., Riazi, S., & Sarv, F. (2025) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-025-01526-6
Joumaa, J. P., Attieh, P., Raffoul, A., Chatrieh, E., Sarkis, C., Harb, F., Azar, S. T., & Ghadieh, H. E. (2025) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2025.30
徐, 玲. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.1582255
Xie, C., Liu, T., Zhong, Y., Li, Z., Xu, J., Zhao, Z., Wang, X., & Gao, P. (2025) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/0118715303396313250904204350
Ocaklı, S., Canlıkarakaya, F., Altunsaray, A., Doğan, İ., Chouseın, B., Karabacak, H., Ceylan, C., & Banlı, O. (2025) · Journal of Medicine and Palliative Care · doi:10.47582/jompac.1767228
Smirnova, E., Siddiqui, M. S., Wilson, L., & Sanyal, A. J. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5797107
Long, H., Guo, R.-Y., Zhou, J., Du, Y., Liu, G.-C., Pan, X.-D., Zeng, Z., & Lin, Y.-E. (2025) · European journal of medical research · doi:10.1186/s40001-025-03628-7
Lin, X.-L., Zeng, Y.-L., Ning, J., Cao, Z., Bu, L.-L., Liao, W.-J., Zhang, Z.-M., Zhao, T.-J., Fu, R.-G., Yang, X.-F., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26122581
Diels, S., Cuypers, B., Tvarijonaviciute, A., Derudas, B., Dijck, E. V., Verrijken, A., Van Gaal, L. F., Laukens, K., Lefèbvre, P., Cerón, J. M. C., et al. (2021) · Figshare · doi:10.6084/m9.figshare.15178712
Li, Z., Yang, N., He, L., Wang, J., Ping, F., Li, W., Xu, L., Zhang, H., & Li, Y. (2023) · Figshare · doi:10.6084/m9.figshare.22600436
Sharmine, S., Unger, L., Altankhuyag, A., Legøy, T. A., Ghila, L., & Chera, S. (2025) · Research Square · doi:10.21203/rs.3.rs-8013440/v1
Zubeir, Z., Nkrumbih, Z., Ally, S. N., & Hadi, Y. H. (2025) · Dr Sulaiman Al Habib Medical Journal · doi:10.4103/dshmj.dshmj_35_25
Chen, H., Liu, W., Zhou, D. D., Liu, S., Guan, Y., Miao, Z., Cai, L., Li, X., Li, Y., Huang, Z., et al. (2026) · Animal Models and Experimental Medicine · doi:10.1002/ame2.70124
Rethinking Liver Transaminases to Predict Diabetes Risk in Children With MASLD
Manco, M., & Gastaldelli, A. (2026) · Diabetes Care · doi:10.2337/dci25-0135
Self-citationDeLacey, S. E., Chen, W., Ranganna, A., Feng, S., Fishbein, M. H., & Bianco, M. E. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70211
Njeim, R., Abureesh, O., Sohail, A., Tam, R., & Deeb, L. S. (2026) · Livers · doi:10.3390/livers6030035
Xuli, W., & Wang, B. Q. (2026) · Journal of International Medical Research · doi:10.1177/03000605261446157
Garrido, N. J., Suárez, M., & Mateo, J. (2026) · World Journal of Hepatology · doi:10.4254/wjh.v18.i5.117567
Negroni, A., Pieroni, L., Fiaschini, N., Palone, F., Mancuso, M., & Vitali, R. (2026) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.70047
Mukherjee, B., Bose, C., Pramanik, S., Kundu, S., Saha, C., Mondal, A., Roy, S. S., & Mukhopadhyay, S. (2026) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2026-005947
Nie, J., Zhou, J., Yuanjia, H., Zhang, C., Yu, P., & Lei, X. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s590383
Bao, Y., Lu, S., Yang, W., Liu, X., Ge, W., Liu, G., Cai, W., Chen, L., & Wang, Y. (2026) · Research Square · doi:10.21203/rs.3.rs-9858751/v1
Petrakis, V., Rafailidis, P. I., Grapsa, A., Sousanidou, A., Bougiouklou, T., Babaka, N., Panagopoulos, P., & Papazoglou, D. (2026) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2897-4761
Mostafai, R., Nachvak, S. M., Saber, A., Mahaki, B., Jalilian, N., Behbood, L., Salehi, M. G., Heidarpour, B., & Hassankiadeh, R. F. (2026) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-026-05249-x
Miya, A., Tura, A., Shokouhmehr, A., Esposito, I., Yavas, A., Granderath, F. A., Schlensak, M., Huttasch, M., Xourafa, G., Heilmann, G., et al. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113481
Oral Hypoglycemic Therapy in Metabolic Dysfunction-Associated Fatty Liver Disease
Karshina, O. O., Sabirov, I. S., & Mohammad, E. A. (2026) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-240-8-110-118
Liver fibrosis risk: a silent threat in type 1 diabetes mellitus
Altıntop, S. E., Barlas, T., Kılıç, A. C. K., Sabur, R. E., Kart, S., Aktürk, M., Toruner, F. B., & Altınova, A. E. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-03009-9
Theocharidou, E., Arvanitakis, K., Koufakis, T., Tsochatzis, E. A., Francque, S., & Germanidis, G. S. (2026) · Drugs · doi:10.1007/s40265-026-02362-6 · Cited by 1
Sarkar, A., Banerjee, T., De, A., Paul, A., Bhowmik, R., Ghosh, N., Dewanjee, S., Bala, A., & Karmakar, S. (2026) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgag094
Chirapongsathorn, S., & Tacke, F. (2026) · Digestion · doi:10.1159/dig/acmag014
Eighty Years After Vague: Advances in Understanding Ectopic Fat and Metabolic Dysfunction
Conte, C., Sumithran, P., le Roux, C. W., Miras, A. D., & Gaal, L. V. (2026) · Obesity Reviews · doi:10.1111/obr.70229
Transcriptional and epigenomic analysis of insulin sensitivity in human adipocytes
Zhang, Q., Zhou, A., Maynard, A. G., Emont, M. P., Jacobs, C. L., Nagesh, S., Batista, T. M., Gibson, R. M., Huang, Y., Kaalia, R., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.118042
Tsaryk, I., Pashkovska, N. V., & Pankiv, V. І. (2026) · CHILD`S HEALTH · doi:10.22141/2224-0551.21.6.2026.1973
Corrao, S., & Argano, C. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1920879
Leiva, E. G., Barb, D., Kalavalapalli, S., Rocha, A. O., CUERVO-PARDO, N., Sharma, A., SAENZ, E. V., Lomonaco, R., MARANGI, S. A., SHETTY, S. S., et al. (2026) · Diabetologia · doi:10.1007/s00125-026-06904-1
Self-citationSalawu, M. O., Moronfolu, I. A., & Yusuf, B. O. (2026) · Pharmacological Research - Natural Products · doi:10.1016/j.prenap.2026.100905
Atractylenolide III alleviates MASLD by inhibiting lipid synthesis and apoptosis via PTEN
Shen, X., Chen, L., Lian, Y., Zhang, Y., Mei, H., Qiu, J., Lu, D., Jiang, Y., & Dou, X. (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.158894
Berteaux, A., Gignac, T., Beaulieu, S., Gagnon, C., Larose, É., Vohl, M., Marette, A., & Carreau, A. (2026) · Metabologia · doi:10.1007/s44357-026-00029-z
Metadata
- Authors
- Gastaldelli, A., & Cusi, K.
- Affiliations
- Istituto di Fisiologia Clinica (IT)
- University of Florida (US)
- Corresponding author
- Gastaldelli, Amalia
- Cusi, Kenneth
- Venue
- JHEP Reports
- Publisher
- Elsevier BV
- Published
- 2019-10
- Volume
- 1
- Issue
- 4
- Pages
- 312-328
- ISSN
- 2589-5559 (ISSN-L)
- PMC
- PMC7001557
- OpenAlex
- W2963543751
- Cited by
- 455
- References
- 231
- Citations by year
- 2026: 48 · 2025: 69 · 2024: 85 · 2023: 74 · 2022: 62 · 2021: 78 · 2020: 34 · 2019: 3
- FWCI
- 6.46
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- JHEP Reports (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Horizon H2020 (634413)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
- Keywords
- non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes, insulin resistance, hepatic insulin sensitivity, insulin secretion, liver fibrosis, end-stage liver disease, lipotoxicity, glucotoxicity, adipose tissue dysfunction, obesity, antidiabetic drugs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
